ANI Pharmaceuticals, Inc. (ANIP) is a publicly traded Healthcare sector company. As of May 21, 2026, ANIP trades at $82.00 with a market cap of $1.80B and a P/E ratio of 19.96. ANIP moved +2.07% today. Year to date, ANIP is +4.25%; over the trailing twelve months it is +35.22%. Its 52-week range spans $52.50 to $99.50. Analyst consensus is strong buy with an average price target of $115.20. Rallies surfaces ANIP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ANI Pharmaceuticals Q1 Revenue Rises 24% to $124.7M, EBITDA Climbs 30%: ANI Pharmaceuticals reported Q1 2026 revenue of $124.7 million, a 24% year-over-year increase driven by higher volumes in its generic contract manufacturing segment. Adjusted EBITDA rose 30% to $23.6 million and management reaffirmed full-year revenue guidance of $520 million to $540 million with a 21%–22% EBITDA margin target.
| Metric | Value |
|---|---|
| Price | $82.00 |
| Market Cap | $1.80B |
| P/E Ratio | 19.96 |
| EPS | $4.11 |
| Dividend Yield | 0.00% |
| 52-Week High | $99.50 |
| 52-Week Low | $52.50 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $923.71M |
| Net Income | $92.15M |
| Gross Margin | 0.00% |
7 analysts cover ANIP: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $115.20.